⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 24, 2025

Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial

Janghee Woo Tingting Zhai Fang Yang Huilei Xu Margaret L. Healey Denise P. Yates Michael T. Beste David P. Steensma

View at Publisher

Ask AI

Bookmark

Share

Key Points

Clonal hematopoiesis mutations influence lung cancer incidence in patients not receiving canakinumab.
Incidence rates of lung cancer vary based on the dosage of canakinumab administered in the CANTOS trial.
This analysis highlights key findings from Supplementary Figure S2 related to cancer incidence.
Understanding treatment effects can help refine cancer prevention strategies in patients with these mutations.

Implication

Analysis shows lung cancer incidence by treatment and clonal hematopoiesis mutations, suggesting dosage effects matter.

Abstract

Supplementary Figure S2 shows cumulative incidence of lung cancer by treatment in patients without CH mutations, stratified by the canakinumab dose.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Woo et al. (2025) studied this question.

synapsesocial.com/papers/689a0627e6551bb0af8ce0ea https://doi.org/10.1158/1940-6207.29636071

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial2025
2Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial2024
3Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial2024
4Supplementary Figure S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial2024
5Supplementary Figure S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial2024

Supplementary Figure S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial2025
Supplementary Figure S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial2025
Data from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial2024